Another study conducted by Shen et al. [90] showed that upregulation of miR-202 improved the bortezomib sensitivity but reduced dexamethasone and thalidomide sensitivity to MM cells through targeting the JNK/SAPK signaling pathway. Here, MAPK9 is linked to Miyoshi myopathy.